*The authors reply below:
Sir, We agree with Dr Price that the intention of treating advanced breast cancer should be to preserve quality and quantity of life, but why does he argue that combination chemotherapy is to be preferred simply because it may produce higher response rates? Selective referencing from articles largely over 10 years old, may produce evidence to support such a conception, but there is, in fact, little evidence from randomized studies that combination therapy does produce higher response rates than single agent, adriamycinl. There is also very little evidence from Dr Price's former colleagues that the improvement of response rates obtained by using chemotherapy substantially prolongs life 2 • Is Dr Price correct in arguing that we should have used adriamycin? Again we would answer no. All published randomized studies that we are aware of indicate that epirubicin produces at least equal response rates but with less toxicity to adriamycin whether used as single agent or in combinationv'. Our choice of a weekly regimen is also appropriate because this approach seems to offer preservation of objective response, but with diminution of side effects", We agree with the statement that mode of delivery alters the side effects of drugs: Dr Price appears not to grasp that was the whole point of our study. Previous studies have indicated anthracycline infusions to be as effective as bolus doses when both have been used every 3 weeks again with reduced toxicity", It therefore appeared logical to investigate the use of weekly infusion epirubicin and by doing so we have avoided the almost universal alopecia, that is often only 'temporary' until death intervenes. Dr Price considers this side effect unimportant: we remain unconvinced his patients would agree.
Working within the strict financial limitations of the NHS we are keen to avoid repeated and costly admissions for infusion therapy and have managed successfully to treat patients in this way as outpatients largely without the need for any antiemetics. The issue of the value of the addition of chemotherapy to tamoxifen as adjuvant treatment for early breast cancer is irrelevant to our preliminary communication on advanced breast cancer chemotherapy. We have corresponded with Dr Price on this subject elsewhere questioning the ethics of advocating adjuvant polychemotherapy for postmenopausal women'-". We think that our recommendations are ethical as they are supported by the majority in this country. We accept that Dr Price may rationally hold different opinions. Recent evidence from America now suggests that thromboembolic complications may be added to the hazards of adjuvant chemotherapy". In fact, American opinion now appears to be against the use of adjuvant chemotherapy in postmenopausal women'". Where does this leave Dr Price? We trust he will also be interested in the overview on this topic, due to be published shortly, which fails to corroborate his views!'. We wish for no monopoly on caring about patients quality of life, and we hope that Dr Price is concerned sufficiently to be documenting the subjective changes his intensive treatments produce. S R EBBS M BAUM
